Licensing deal could enable bundling of antipsychotics with management technology.
Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.